Abstract: The disclosed principles describe systems and methods for assessing the security posture of a target device, wherein the assessment is performed by a scanning computer in communication with the target device via a communication network. By employing a system or method in accordance with the disclosed principles, distinct advantages are achieved. Specifically, conducting such a remote scan allows for the scanner computer to perform a remote scan of the remote device without installing client software to the remote device. Thus, the disclosed principles reduce the need for internal IT resources to manage the deployment and updates of client software on the target device. Also, conducting a remote scan according to the disclosed principles allows for the remote scan to be performed even if the scanner computer and remote device run different operating systems.

Abstract: A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally, wherein bioequivalency is established by (a) a 90% confidence interval of the relative mean Cmax and AUC of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25, or (b) a 90% confidence interval of the ratios for AUC and Cmax of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25.

Abstract: Methods, compositions, and devices for transdermally administering an active agent such as donepezil are provided.

Abstract: In one example, a strut for mounting a jet engine to a wing of an aircraft includes a plurality of engine mounts and a space frame truss supported from the wing and including front and aft portions, the front portion being coupled to and supporting the engine mounts, the aft portion extending upwardly and rearwardly from an aft end of the front portion. By removing the aft end of the strut from the core exhaust zone of the engine, substantial reductions in the weight and drag of the strut, and a corresponding increase in the specific fuel consumption of the associated aircraft may be achieved.

Abstract: The present disclosure relates to a method and system for indicating energy savings for a distributed site. The energy savings is indicated by an energy management system, which receives energy consumption data of the distributed site for a first observation period. Further one or more service windows are defined for the distributed site and an energy saving strategy is applied to at least one service window. Further, the energy consumption data for the second observation period is received and a compared of one or more service windows of the first observation period with the corresponding service windows of the second observation period is done. The energy management system further determines adjustment factors in the energy profiles based on parameters affecting the energy profiles which were not considered during the first observation period and hence indicate the energy savings for the distributed site based on the first saving and adjustment factor.

Abstract: A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

Abstract: Devices and methods for using and manufacturing microstructure arrays are described.

Abstract: Embodiments include a method for verifying a counter design within a tolerance window within which a race condition occurs between a context event and a design event. The method includes receiving a plurality of events within the counter design, the plurality of events including the context event and the design event. The method also includes dynamically determining the tolerance window around the context event by setting a first portion of the tolerance window to precede an occurrence of the context event and by setting a second portion of the tolerance window to follow the context event. Additionally, the method includes performing a verification of whether the design event is within the first portion of the tolerance window or the second portion of the tolerance window.

Abstract: The disclosed principles describe systems and methods for assessing the security posture of a target device, wherein the assessment is performed by a scanning computer in communication with the target device via a communication network. By employing a system or method in accordance with the disclosed principles, distinct advantages are achieved. Specifically, conducting such a remote scan allows for the scanner computer to perform a remote scan of the remote device without installing client software to the remote device. Thus, the disclosed principles reduce the need for internal IT resources to manage the deployment and updates of client software on the target device. Also, conducting a remote scan according to the disclosed principles allows for the remote scan to be performed even if the scanner computer and remote device run different operating systems.

Abstract: Formulations for topical application of aripiprazole are provided. The formulations, when applied topically to the skin of a subject, provide a therapeutic amount of aripiprazole in the blood for a sustained period of time for treatment of conditions responsive to aripiprazole including but not limited to depression, schizophrenia, and bipolar disorder.

Abstract: A running board for a vehicle includes a base member mountable to a vehicle. The base member has a first end, a second end, and an intermediate portion extending therebetween defining a longitudinal axis. A selectively deployable step member is mounted to the base member. The selectively deployable step member is selectively slidable relative to the base member along the longitudinal axis.

Abstract: In one example embodiment, a strut for mounting a jet engine to a wing of an aircraft includes a plurality of engine mounts and a space frame truss supported from the wing and comprising front and aft portions, the front portion being coupled to and supporting the engine mounts, the aft portion extending upwardly and rearwardly from an aft end of the front portion. By removing the aft end of the strut from the core exhaust zone of the engine, substantial reductions in the weight and drag of the strut, and a corresponding increase in the specific fuel consumption of the associated aircraft may be achieved.

Abstract: A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally, wherein bioequivalency is established by (a) a 90% confidence interval of the relative mean Cmax and AUC of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25, or (b) a 90% confidence interval of the ratios for AUC and Cmax of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25.

Abstract: A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally, wherein bioequivalency is established by (a) a 90% confidence interval of the relative mean Cmax and AUC of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25, or (b) a 90% confidence interval of the ratios for AUC and Cmax of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25.

Abstract: A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

Abstract: Compositions, devices, and methods for transdermal administration of active agents provided in their salt form instead of neutral form are provided.

Abstract: Transdermal delivery systems for the systemic delivery of memantine are described, wherein the system comprises a drug reservoir layer and an adhesive layer, optionally together with one or more intermediate and/or supporting layers, wherein the drug reservoir layer comprises an acrylate polymer or copolymer, a permeation enhancer, a carrier, and memantine base generated in situ by reaction of a memantine salt and an alkaline salt. Compositions and kits comprising the various components, e.g., drug reservoir and/or adhesive compositions are described. Methods relating to treatment of CNS disorders, e.g., Alzheimer's disease and/or dementia, using the aforementioned transdermal delivery devices and/or compositions are also described.

Abstract: A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

Abstract: Compositions, devices, and methods for transdermal administration of active agents provided in their salt form instead of neutral form are provided.

Abstract: A method and system for providing personalized and confidential data management and sharing services to the subscriber are disclosed. The method includes enabling an individual to register with a personalized and confidential data management and sharing system to become a subscriber. The subscriber may enter personalized and confidential data and designate recipients to receive personalized and confidential data and upload photographs of the recipients. The method includes determining the existence of the subscriber by tracking the visiting/login history of the subscriber at regular intervals, transmitting communication messages to the personalized digital account of the subscriber upon identifying the subscriber not logging in to the subscriber account and establishing a voice call with the contact number of the subscriber and/or the affiliates to confirm the demise/existence of the subscriber.